Group One Trading
FHTX icon

Group One Trading’s Foghorn Therapeutics FHTX Stock Holding History

Group One Trading’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-200
Closed -$978 – 8444
2025
Q3 		$978 Hold
200
– – ﹤0.01% 8059
2025
Q2 		$940 Buy
+200
New +$836 ﹤0.01% 7577

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Group One Trading's FHTX Position: Q4 2025 in Review

Group One Trading sold out of Foghorn Therapeutics (FHTX) in Q4 2025, closing a stake of 451 shares — an estimated $2.21K sold.

Group One Trading first reported a position in FHTX in Q3 2022 and held it in 8 quarters. The position peaked at $4.22K in Q2 2023. 93 funds tracked by Wall St. Rank hold FHTX as of Q4 2025.

  • Group One Trading reported no remaining Foghorn Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Group One Trading sold 451 Foghorn Therapeutics shares in Q4 2025, an estimated $2.21K.
  • Group One Trading first reported a position in Foghorn Therapeutics in Q3 2022 and held it in 8 quarters.
  • Group One Trading's Foghorn Therapeutics position peaked at $4.22K in Q2 2023.
  • 93 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q4 2025.

Based on Group One Trading's 13F filing for Q4 2025, filed 12 Feb 2026.